Efficacy of topical pimecrolimus in the treatment of chronic vulvar pruritus: A prospective case series - A non-controlled, open-label study

Journal of Dermatological Treatment

Volumn 17, Issue 5, 2006, Pages 276-278

  Sarifakioglu, Evren ^a   Gumus, Ilknur Inegol ^a  

^a FATIH UNIVERSITY   (Turkey)

Author keywords

Pimecrolimus; Vulvar disease; Vulvar pruritus

Indexed keywords

PIMECROLIMUS;

ADULT; ARTICLE; CASE STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; CREAM; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SELF EVALUATION; STATISTICAL ANALYSIS; VULVA PRURITUS;

ADMINISTRATION, CUTANEOUS; ADULT; CHRONIC DISEASE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; PRURITUS VULVAE; TACROLIMUS; TREATMENT OUTCOME;

EID: 33750138198     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630600823351     Document Type: Article

References (7)

1. Lonsdale-Eccles AA, Velangi S. Topical pimecrolimus in the treatment of genital lichen planus: a prospective case series. Br J Dermatol. 2005;153:390-4.
2. Städer S, Luger TA. Antipruritische wirkung von pimecrolimus und tacrolimus. Hautarzt. 2003;5:413-17.
3. Kelly RA, Foster DC, Woodruff JD. Subcutaneous injection of triamcinolone acetonide in the treatment of chronic vulvar pruritus. Am J Obstet Gynecol. 1993;169:568-70.
4. Thaçi D, Steinmeyer K, Ebelin ME, Scott G, Kaufmann R. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, effective. Dermatology. 2003;207:37-42.
5. Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosis. J Reprod Med. 2004;49:778-80.
6. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol. 1999;141:264-73.
7. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for four weeks. A randomized, double-blind controlled study. Br J Dermatol. 2001;144:507-13.